Renalytix PLC Total Voting Rights
July 30 2024 - 1:00AM
RNS Regulatory News
RNS Number : 2520Y
Renalytix PLC
30 July 2024
Renalytix
plc
("Renalytix" or the "Company")
Total Voting
Rights
LONDON and NEW YORK, 30 July
2024 - Renalytix
plc (NASDAQ: RNLX) (LSE: RENX) announces that at today's date,
the Company's total issued share capital is 165,925,513 Ordinary Shares
of £0.0025 each in the capital of
the Company ("Ordinary Shares"). Each Ordinary Share carries the
right to one vote at a general meeting of the
Company. The
Company does not hold any Ordinary Shares in treasury.
The above figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
Paul McManus / Alice
Woodings
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
Mob: 07980
541 893 / 07407 804 654
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or
investors@renalytix.com
|
|
| |
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an artificial intelligence enabled in-vitro diagnostics and laboratory
services company that is the global founder and leader in the field
of bioprognosis™ for kidney health. In late 2023, our
kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages
1-3b) risk assessment for progressive decline in kidney function in
T2D patients. By understanding how disease will progress, patients
and clinicians can take action earlier to improve outcomes and
reduce overall health system costs. For more information,
visit
www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRQKCBDNBKDQOB
Renalytix (LSE:RENX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Sep 2023 to Sep 2024